Here’s how analysts see Zosano Pharma Corp (NASDAQ:ZSAN) after this past week.

September 13, 2017 - By Adrian Erickson

 Here's how analysts see Zosano Pharma Corp (NASDAQ:ZSAN) after this past week.

Zosano Pharma Corp (NASDAQ:ZSAN) Ratings Coverage

Among 3 analysts covering Zosano Pharma (NASDAQ:ZSAN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Zosano Pharma had 5 analyst reports since September 29, 2015 according to SRatingsIntel. TH Capital maintained it with “Buy” rating and $11 target in Tuesday, September 29 report. The rating was maintained by Roth Capital with “Buy” on Wednesday, November 11. Ladenburg Thalmann downgraded Zosano Pharma Corp (NASDAQ:ZSAN) on Thursday, August 11 to “Neutral” rating. The company was maintained on Tuesday, September 29 by Roth Capital. The stock of Zosano Pharma Corp (NASDAQ:ZSAN) has “Buy” rating given on Wednesday, November 11 by TH Capital. Below is a list of Zosano Pharma Corp (NASDAQ:ZSAN) latest ratings and price target changes.

The stock increased 2.88% or $0.026 during the last trading session, reaching $0.916. About shares traded. Zosano Pharma Corp (NASDAQ:ZSAN) has declined 31.28% since September 13, 2016 and is downtrending. It has underperformed by 47.98% the S&P500.

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The company has market cap of $35.92 million. The Firm has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. It currently has negative earnings. The Company’s microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

More notable recent Zosano Pharma Corp (NASDAQ:ZSAN) news were published by: Marketwatch.com which released: “0.90” on August 03, 2014, also Nasdaq.com with their article: “Zosano Pharma Corp (ZSAN) President, CEO Konstantinos Alataris Bought $168153 …” published on August 23, 2016, Globenewswire.com published: “Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA” on June 26, 2017. More interesting news about Zosano Pharma Corp (NASDAQ:ZSAN) were released by: Globenewswire.com and their article: “Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update” published on August 10, 2017 as well as Globenewswire.com‘s news article titled: “Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly …” with publication date: August 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.